The US Food and Drug Administration has approved a supplemental biologics license application letting Eisai and Biogen market LEQEMBI IQLIK, the subcutaneous injection formulation of lecanemab-irmb, as initial therapy for early Alzheimer's disease, the companies said in a joint announcement dated July 13, 2026 (local time). The FDA had already cleared the same formulation for maintenance dosing in August 2025; this approval extends it to the start of treatment.
The mechanics matter more than the paperwork. The newly approved initial-therapy regimen is two 250 mg injections, 500 mg total, delivered once a week through an autoinjector, with each injection taking about 15 seconds. After 18 months of initial therapy by either intravenous or subcutaneous route, patients move to a maintenance dose of 360 mg weekly, also by injection. Patients and doctors can switch between IV and subcutaneous administration across both phases.
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Initial therapy (newly approved) | 500 mg (two 250 mg injections) | Weekly | Each injection takes about 15 seconds via autoinjector; IV route also remains an option |
| Maintenance (after 18 months of initial therapy) | 360 mg | Weekly | Follows completion of initial therapy by either IV or subcutaneous route |
The approval rests on a substudy within the long-term extension of the Clarity AD trial, which had tested lecanemab in early Alzheimer's patients over an 18-month core period. Weekly subcutaneous dosing produced drug exposure comparable to IV infusion, with similar clinical and amyloid-clearance benefits, according to the release. The safety profile was described as broadly similar to IV dosing, with injection-site reactions mostly local rather than systemic.
Eisai frames the operational upside in specific terms: less time spent at clinics for patients and care partners, reduced dependence on infusion-related medical resources, shorter prep and administration time, lighter monitoring burden for nurses, and preserved infusion capacity for patients who still need IV treatment. A separate acceptability study, based on in-person interviews with 50 early Alzheimer's patients and 50 care partners using a training autoinjector without needles or drug, found 94% rated the device easy to use.
Howard Fillit, cofounder and chief science officer of the Alzheimer's Drug Discovery Foundation, is quoted in the release calling the initial-therapy approval a step that gives patients and care partners a meaningful choice in how anti-amyloid treatment is administered.
The initial-therapy version of LEQEMBI IQLIK is due to launch in the US in late August 2026, available through specialty pharmacies. Eisai's TDnet filing states the financial impact on its consolidated forecast for the year to March 2027 will be minimal, with no change to guidance issued on May 15, 2026. Support for patients includes the LEQEMBI Companion program for insurance and cost information, a copay assistance program for eligible patients, and a Patient Assistance Program that provides the drug free to qualifying uninsured patients who meet financial criteria.